Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pleural mesothelioma.

P Ruffie1

  • 1Institut Gustave Roussy, Villejuif, France.

Current Opinion in Oncology
|April 1, 1992
PubMed
Summary

Diffuse pleural malignant mesothelioma (DMM) is a rare asbestos-related cancer. Research highlights challenges in diagnosis and poor treatment outcomes, emphasizing the need for new therapeutic strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Pulmonary blastoma in an adult].

Revue des maladies respiratoires·2010
Same author

[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].

Revue de pneumologie clinique·2010
Same author

[Evaluating the nutritional status of a lung cancer patient is an important element in patient management].

Revue de pneumologie clinique·2008
Same author

[Fever and infectious complications in patient with lung cancer].

Revue de pneumologie clinique·2008
Same author

[Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic].

Revue de pneumologie clinique·2008
Same author

[Malignant pleural mesothelioma: role of excisional surgery].

Revue des maladies respiratoires·2007

Area of Science:

  • Oncology
  • Pathology
  • Asbestos-related diseases

Background:

  • Diffuse pleural malignant mesothelioma (DMM) is a rare cancer, often linked to asbestos exposure.
  • Distinguishing DMM from other pleural conditions like adenocarcinoma can be diagnostically challenging.
  • Current therapeutic outcomes for DMM are generally poor, with limited curative options.

Purpose of the Study:

  • To review the diagnostic challenges and therapeutic limitations of DMM.
  • To highlight the need for improved diagnostic tools and treatment strategies for DMM.
  • To explore the potential of novel therapies, including immunotherapy, for DMM.

Main Methods:

  • Review of diagnostic markers including immunohistochemistry and electron microscopy.
  • Analysis of treatment outcomes for DMM, including surgery, radiation, and chemotherapy.
  • Exploration of preclinical data on immunotherapy agents like interferons and interleukins for DMM.

Main Results:

  • Immunohistochemical markers and electron microscopy assist in differentiating DMM from adenocarcinoma.
  • DMM is largely chemoresistant, and local treatments are often difficult due to disease extent.
  • In vitro and in vivo models show mesothelial cells are sensitive to cytokines and immune cells, suggesting immunotherapy potential.

Conclusions:

  • Improved diagnostic methods are crucial for timely DMM management.
  • Novel therapeutic approaches, particularly immunotherapy and combination therapies, show promise for DMM.
  • Further research using cell lines and animal models is essential for preclinical evaluation of new DMM treatments.

Related Experiment Videos